ZUMA-7 : A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma,Follicular Lymphoma,Lymphoma,T-Cell Lymphoma

Trial Overview Read MoreRead more

This phase III trial is comparing the effectiveness of a biological therapy (Axicabtagene Ciloleucel) and standard of care chemotherapy in Diffuse Large B-Cell Lymphoma patients who have gotten worse or not responded to prior treatment.
 

This trial is treating patients with Diffuse Large B-Cell Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Commercial Sponsor

Gilead Sciences, Inc.

Summary

Eligible patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) after first-line rituximab and anthracycline-based chemotherapy, will be randomised 1:1 to receive the investigational therapy (axicabtagene ciloleucel) or standard of care chemotherapy. Patients that are randomised to receive axicabtagene ciloleucel will have a singe intravenous infusion of chimeric antigen receptor (CAR)-transduced autologous T cells, following conditioning chemotherapy. Patients randomised to receive standard of care chemotherapy will be given one of the following regimens - R-ICE, R-DHAP, R-ESHAP, or R-GDP - as selected by the investigator. Standard of care chemotherapy will be followed by high dose therapy (eg, BEAM) and an autologous stem cell transplant for responders.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next